"CV Therapeutics' Phase III Strong With Regadenoson." BIOWORLD Today. AHC Media L.L.C. 2009. HighBeam Research. 30 Apr. 2016 <https://www.highbeam.com>.
"CV Therapeutics' Phase III Strong With Regadenoson." BIOWORLD Today. 2009. HighBeam Research. (April 30, 2016). https://www.highbeam.com/doc/1G1-211112659.html
"CV Therapeutics' Phase III Strong With Regadenoson." BIOWORLD Today. AHC Media L.L.C. 2009. Retrieved April 30, 2016 from HighBeam Research: https://www.highbeam.com/doc/1G1-211112659.html
West Coast Editor
CV Therapeutics Inc.'s regadenoson to boost coronary blood flow for better myocardial perfusion imaging hit the primary endpoint in the first of two pivotal Phase III studies, and the company is awaiting results from the second trial.
The company's stock (NASDAQ:CVTX) closed Thursday at $26.48, up 65 cents.
"We obviously need to report results in the second Phase III, which is the same study design," Louis Lange, CEO of the Palo Alto, Calif.-based company, said during a conference call. If that second trial also proves positive, a new drug application would be filed "sometime next year," he said.
The first trial, though not designed to show "p" values, demonstrated with 95 percent confidence that MPI work done with the selective A2A adenosine receptor agonist regadenoson were comparable to those conducted with Adenoscan (adenosine), the leading agent for MPI studies in the U. …
BIOWORLD Today; November 3, 2009
BioWorld Week; November 3, 2003
BioWorld Week; May 3, 2004
Drug Week; November 28, 2003
BioWorld Week; August 15, 2005
Browse back issues from our extensive library of more than 6,500 trusted publications.
HighBeam Research is operated by Cengage Learning. © Copyright 2016. All rights reserved.
The HighBeam advertising network includes: womensforum.com GlamFamily